Nasdaq · Biotech stocks database
ORGO (Organogenesis Holdings Inc.) stock: $0.81, $104.6M market cap, $21.3M cash, $83.3M EV, $114.8M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have Premarket Application (“PMA”) approval, or 510(k) clearance from the United States Food and Drug Administration (“FDA”). Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $21.3M |
|---|---|
| Debt | $0.0M |
| Net cash | $21.3M |
| Enterprise value | $83.3M |
| Basic shares | 129.8M shares |
| Fully diluted shares | 141.7M shares |
| Fully diluted market cap | $114.8M |
| Cash per share | $0.16 |
| Quarterly burn | $31.7M |
| Cash runway | 1.5 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Cap table as of 2026-06-30.
Loading ORGO daily closes…
ReNu (proposed Amnuvx) · Apr 24, 2027 · guided in 6 mo